Response to Nivolumab treatment in patients with non small cell lung cancer : a retrospective study
Latest Information Update: 05 Feb 2019
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer